BioCryst to Maintain Orladeyo Sales While Shifting Focus from Internal R&D to External Partnerships
Decision to Halt Internal Drug Development and Reduce Costs
BioCryst Pharmaceuticals (BCRX) has decided to discontinue its internal drug discovery programs and close its research facility in Birmingham, Alabama, by the end of 2026. This strategic decision aims to streamline operations and secure financial stability by eliminating inefficient early-stage research. As a result of this restructuring, the company has lowered its 2026 non-GAAP operating expense guidance from $450 million to $470 million to $420 million to $440 million, a reduction of approximately $30 million. This reduction in fixed costs is expected to significantly contribute to the company's ability to focus on late-stage clinical development of promising pipeline assets and establish external partnerships.
Shift to an Open Innovation Business Model Focused on External Innovation and Partnerships
BioCryst is now transitioning to an open innovation model, prioritizing the acquisition (license-in) or co-development of external technologies rather than relying solely on internal early-stage drug development. This shift reflects the company's belief that avoiding the high risks associated with early discovery and incorporating validated external assets is the best path to long-term shareholder value. In January, the company signaled its commitment to this strategy by acquiring Astria Therapeutics, which holds the hereditary angioedema (HAE) treatment Navenibart, for approximately $700 million.
Strong Orladeyo Sales and Resumption of Pediatric Formulation Supply
Fortunately, the company's core commercial asset, Orladeyo (berotralstat), an oral preventive treatment for hereditary angioedema (HAE), is expected to generate net sales of $625 million to $645 million in 2026, consistent with previous guidance. The recent manufacturing delays of the pediatric (ages 2 and older) pellet formulation have been successfully resolved, and the product is expected to be fully available in the market by early August 2026. This will help solidify the company's market share, generate consistent cash flow, and address an unmet need for patients by providing a more convenient dosage form.
Focus on Key Clinical Pipeline Assets, Including Navenibart and Subsequent Assets
While internal discovery efforts are being discontinued, the development of Navenibart (formerly STAR-0215), a late-stage plasma kallikrein inhibitor, remains a top priority. A Phase 3 clinical trial (ALPHA-ORBIT) is currently underway to evaluate Navenibart for the prevention of hereditary angioedema, with topline data expected in the third quarter of 2027 and a planned FDA submission by the end of the year. In addition, Phase 1 proof-of-concept data for BCX17725, a KLK5 inhibitor for the treatment of Netherton syndrome, is expected to be available by the end of 2026, indicating that the company's strategy to maximize the value of its late-stage pipeline is on track.
The closure of the R&D department and the $30 million reduction in annual operating expenses represent a necessary financial decision for BioCryst to optimize cash flow as a commercial-stage company. In the global hereditary angioedema (HAE) market, estimated at $2 billion to $3 billion, Orladeyo, a once-daily oral preventive treatment, is poised to capture up to $645 million in annual sales, establishing a unique position in the market dominated by injectable therapies such as Takeda's Takhzyro. Furthermore, with the acquisition of Astria Therapeutics for $700 million, the company has secured Navenibart, which is currently in Phase 3 clinical trials (ALPHA-ORBIT) with topline data expected in the third quarter of 2027, positioning the company for strong late-stage growth. However, with the impending market entry of new competitive drugs such as Ionis/AstraZeneca's donidalorsen, accelerating the development of its Phase 3 pipeline and promptly filling the gap in its early-stage pipeline through new licensing agreements will be critical for the company's long-term success.